NICE issues draft guidance on dupilumab for treating severe asthma for consultation

In DRAFT guidance, NICE does not recommend dupilumab as add-on maintenance therapy for inadequately controlled severe asthma with type 2 inflammation in those on maintenance therapy with high-dose inhaled corticosteroids and another maintenance treatment.


National Institute for Health and Care Excellence